Agilent & Taros partner for “Automated Purification”
More output, better quality, faster delivery times
May 2014 ++++
Purification of target compounds is a critical step during chemical matter generation faced by all synthetic organic chemists. Specifically, medicinal chemists in drug discovery require effective, robust purification of compound libraries in order to properly assess their biological activities. Very often, successful purification involves several labor inensive analytical and preparative method development steps.
To enhance our Dortmund-based compound library production capacity and to increase overall throughput of delivered compounds at a highest level of quality, we have invested into Agilent’s 1260 and 1290 Infinity Series equipment, a truly automated LC/MS-system supporting analytical and preparative purification workflows with minimal method development or scale-up work.
This unique layout has been developed in close collaboration between Agilent Technologies and Taros and recently presented through a dedicated CE&N webinar.
About Taros Chemicals
Taros is a privately owned discovery chemistry company, working with global pharmaceutical, biotech and chemical companies since 1999. Alongside our performance chemicals and material science division, Taros’ drug discovery mission is to create drug candidates as potential new medicines. Taros has a strong scientific track record on many biomolecular targets in all main therapeutic areas and thereby adding considerable value to collaborations from target validation and hit identification to lead generation and optimization. Taros’ core expertise ranges from custom synthesis and process development to modern medicinal and computational chemistry, as well as compound library design and production.
Taros was heading the chemistry efforts of the EUR 196 million funded European Lead Factory (2013-2018) and is currently heading its EUR 36.5 million funded continuation (2019-2022). Moreover, Taros is deeply engaged in other research alliances like the EUR 11 million funded Drug Discovery Hub Dortmund.
Youri R. Mesmoudi, Executive Vice President, e-mail: innovation |at| taros.de
As a leading contract research organization in discovery chemistry and custom synthesis, Taros provides comprehensive solutions to meet our clients’ needs from diverse branches and applications
Our experienced chemists practice a pragmatic culture and customer-centric approach in order to exceed project expectations, despite challenges, bridging very narrow timelines. They are trained to consider economic, safety and ecological boundaries and conditions laid out for all stages of the project, starting from the development of synthetic routes to…